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Context: Prior studies suggested a role for the arginine vasopressin (AVP) system in the patho-
genesis of diabetes. Prospective studies on the association between copeptin (the C-terminal frag-
ment of AVP hormone) and incident diabetes are limited.
Objective: We have examined the association between plasma copeptin and the risk of incident
diabetes in older men.
Design: The British Regional Heart Study was a prospective study with an average of 13 years
follow-up.
Setting: General practices in the United Kingdom were studied.
Participants: Participants were 3226 men aged 60 to 79 years with no prevalent diabetes.
Outcome: We measured 253 patients with incident diabetes.
Results: Copeptin was positively and significantly associated with renal dysfunction, insulin resis-
tance (homeostasis model assessment of insulin resistance), metabolic risk factors (waist circum-
ference, blood pressure, triglycerides, and liver function), C-reactive protein, tissue plasminogen
activator, and von Willebrand factor (endothelial dysfunction) but not with plasma glucose. The
risk of incident diabetes was significantly elevated only in men in the top fifth of the copeptin
distribution (6.79pmol/L), and this risk persisted after adjustment for several diabetes risk factors
includingmetabolic risk factors and C-reactive protein (adjusted hazard ratio in the top fifth vs the
rest  1.78 [95% confidence interval, 1.34–2.37]). Risk was markedly attenuated although it re-
mained significant after further adjustment forhomeostasismodel assessmentof insulin resistance
and plasma glucose (adjusted hazard ratio  1.47 [1.11–1.97]). The increased risk was seen even
when the analysiswas restricted tomenwith no chronic kidney disease or tomenwith no impaired
fasting glucose (6.1 mmol/L).
Conclusion: Copeptin is associated with a significantly increased risk of diabetes in older men. The
association is partly mediated through lower insulin sensitivity. The findings suggest a potential
role of the AVP system in diabetes. (J Clin Endocrinol Metab 100: 3332–3339, 2015)
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electrocardiogram; eGFR, predicted glomerular filtration rate; GGT, -glutamyl trans-
ferase; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; HOMA,
homeostasis model assessment; HOMA-, homeostasis model assessment of -cell func-
tion; HOMA-IR, homeostasis model assessment of insulin resistance; HR, hazard ratio;
MDC, Malmö Diet and Cancer; PAI-2, plasminogen activator inhibitor-1; PREVEND, Pre-
vention of Renal and Vascular Endstage Disease; tPA, tissue plasminogen activator; vWF,
von Willebrand factor; WC, waist circumference.
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Arginine vasopressin (AVP), also termed antidiuretichormone, is a nonapeptide produced in the hypo-
thalamus. AVP is released from the neurohypophysis to
promote renal water conservation, which affects osmo-
regulation and cardiovascular homeostasis (1, 2). The
AVP system has been postulated to play a role in glucose
homeostasis, insulin resistance, and lipid and fat metab-
olism in human and animal studies (3–6). Vasopressin is
elevated in patients with type 2 diabetes (7). However, the
plasma AVP level is difficult to measure and unreliable
because of its instability and short half- life (8). Plasma
C-terminal provasopressin (copeptin), theC-terminal part
of theAVPprecursor peptide, is stable in serumor plasma,
making it a more convenient biomarker. Copeptin has
been established as a reliable marker of circulating AVP
concentration in routine clinical practice (8). Several
cross-sectional population studies have showncopeptin to
be strongly and positively associated with insulin resis-
tance, obesity and metabolic abnormalities (9–14), and
major risk factors for the development of diabetes. Co-
peptin has shown to be raised in subjects with diabetes
although one study suggested that the association is seen
in men only (13). Prospective studies on the association
between copeptin and the risk of incident diabetes, how-
ever, are limited and the results are inconsistent (14–16).
Among the 3 prospective studies that have examined the
association between copeptin and the risk of incident di-
abetes,TheMalmöDiet andCancer (MDC)Study showed
an association independent of fasting insulin and blood
glucose (14), whereas the FINRISK97 Study showed no
independent association between copeptin and diabetes
after adjustment for metabolic risk factors (16). The Pre-
vention of Renal and Vascular Endstage Disease (PRE-
VEND) Study suggested sex differences in the association
between copeptin and diabetes, reporting an independent
association in women but not in men (15). Insulin resis-
tance is associated with systemic inflammation andmark-
ers of endothelial dysfunction, including tissue plasmino-
gen antigen (tPA) and von Willebrand factor (vWF) (17,
18), which have been related to diabetes incidence (18,
19). The contributing role of these factors to the copeptin-
diabetes relationship has not been previously assessed.
The aim of this study was to examine the prospective as-
sociation between copeptin and the risk of diabetes in
older men and assess the role of insulin and inflammation
and endothelial dysfunction in the association.
Subjects and Methods
The British Regional Heart Study (BRHS) is a prospective study
of cardiovascular disease (CVD) involving 7735 men aged 40 to
59 years, selected from the age-sex registers of 1 general practice
in each of 24 British towns, who were screened between 1978
and 1980 (20). In 1998 to 2000, all surviving men, now aged 60
to 79 years, were invited for a 20th year follow-up examination.
All relevant local research ethics committees provided ethical
approval. All men provided informed written consent to the in-
vestigation, which was carried out in accordance with the Dec-
laration of Helsinki. They completed a questionnaire (Q20) that
included questions on their medical history and lifestyle behav-
ior. The men were requested to fast for a minimum of 6 hours,
during which time they were instructed to drink only water and
then to be present for measurement at a specified time between
8:00 AM and 6:00 PM. Twelve-lead electrocardiograms (ECGs)
were recorded using a Siemens Sicard 460 instrument and were
analyzed using the Minnesota Coding definitions at the Univer-
sity of Glasgow ECG core laboratory. All men were asked to
provide a blood sample, collected using the Sarstedt Monovette
system. A total of 4252 men (77% of survivors) presented for
examination.
Study subjects
Bloodmeasurements of copeptinwere available for3666men
(86%) at the 20-year follow-up examination (1998–2000).Men
with a doctor diagnosis of diabetes, and men with a diagnosis of
diabetes in the year of reexamination and those with a fasting
glucose of 7 mmol/L (World Health Organization criteria)
were considered to have prevalent diabetes and were excluded
(n  426). Men taking vasopressin drugs (n  14) were also
excluded. The analysis is thus based on 3226 men.
Cardiovascular risk factors
Details ofmeasurement and classificationmethods for smok-
ing status, physical activity, waist circumference (WC), social
class, blood pressure (BP), high-density lipoprotein cholesterol
(HDL-C), and triglycerides in this cohort have been described
previously (21–24). Preexisting CVD in men was defined as a
history of a doctor diagnosis of myocardial infarction, stroke, or
heart failure. The longest-held occupation of subjects was used
to define social class using the Registrar Generals’ Social Class
Classification: I (professionals), II (managerial), III nonmanual
(clerical), III manual (skilled), IV manual (partly skilled), and V
manual (unskilled). Manual workers included men in social
classes III manual, IV, and V. Heart rate was measured with an
ECG.Plasmaglucosewasmeasuredbyaglucoseoxidasemethod
using a Falcor-600 automated analyzer (25). Serum insulin was
measured using an ELISA that does not cross-react with proin-
sulin (26). Triglyceride, glucose, and insulin concentrationswere
adjusted for the effects of fasting duration and time of day (24).
Insulin resistance was estimated according to the homeostasis
model assessment (HOMA), the product of fasting glucose
(millimoles per liter) and insulin (units per milliliter) divided by
the constant 22.5 (27). We also calculated the insulin secretory
function as quantified by the homeostasis model assessment of
-cell function (HOMA-) based on fasting insulin and glucose
definedasHOMA-20 insulin (units permilliliter)/(glucose
[millimoles per liter) 3.5) (27).Homeostasismodel assessment
of insulin resistance (HOMA-IR) and HOMA- are highly cor-
related (r  0.81). Predicted glomerular filtration rate (eGFR)
(measure of renal function)was estimated from serum creatinine
using the equation eGFR186 (creatinine)1.154 (age)
0.203 (28). Chronic kidney disease was defined as eGFR of60
mL/min/1.73 m2. Plasma levels of tPA antigen were measured
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with an ELISA (Biopool AB) as was vWF antigen (DAKO) (17).
C-reactive protein (CRP) was assayed by ultrasensitive nephe-
lometry (Dade Behring). -Glutamyl transferase (GGT) was
measured using a Hitachi 747 automated analyzer.
Laboratory methods
Manufacturers’ calibrators and controls were used in the
measurement of copeptin in accordance with their instructions.
Copeptin was measured using an ultrasensitive method on a
BRAHMS Kryptor compact plus (B.R.A.H.M.S.). The lower
limit of sensitivitywas 0.9 pmol/L. The low control coefficient of
variationwas 4.7%, and the high control coefficient of variation
was 4.6% (23).
Follow-up
All men have been followed up for all-cause mortality, car-
diovascular morbidity, and development of type 2 diabetes from
the initial examination to July 2012 (29), and follow-uphas been
achieved for 99% of the cohort. This analysis is based on fol-
low-up from rescreening in 1998 to 2000, a mean follow-up
period of 13 years (12–14 years). Information on deaths was
collected through the established“tagging”procedures provided
by the National Health Service registers. Evidence regarding di-
abeteswas obtained by reports fromgeneral practitioners andby
biennial reviews of the patients’ notes (including hospital and
clinic correspondence) through to the end of the study period.
Statistical methods
The distribution of copeptin was skewed, and log transfor-
mation was used. The men were divided into equal fifths based
on the copeptin distribution in all men. The Cox proportional
hazards model was used to initially assess the age-adjusted haz-
ard ratio (HR) (relative risk) in a comparison of quintiles of
copeptin. Because of a threshold effect of copeptin on incident
diabetes, subsequent analyses were performed to adjust for po-
tential confounders and mediators in a stepwise manner, com-
paring the top fifth vs the rest. In multivariate analyses, smoking
(never, long-term ex-smokers [15 years], recent ex-smokers
[15 years], and current smokers), social class (manual vs non-
manual), physical activity (4 groups), use of antihypertensive
treatment (yes/no), statin use (yes/no), andpreexistingCVD(yes/
no) were fitted as categorical variables. WC, systolic BP, triglyc-
erides, HOMA, GGT, CRP, eGFR, plasma glucose, and vWF
were fitted as continuous variables. Receiver operating charac-
teristic curves and areas under the curve (C-statistic) were used
to assess the incremental value of copeptin to predict diabetes
beyond a basic score, which included routine risk factors for
diabetes readily obtainable in clinical practice, eg, age, WC,
smoking, hypertension, use of statins, antihypertensive drugs,
preexistingCVD, renal function,GGT, triglycerides, and fasting
blood glucose. We calculated risk function estimates based on
the regression coefficients of the Cox models with and without
copeptin in the model. Tests for differences between the C-sta-
tistics for the risk function models with and without copeptin
were performed using an SASmacro (% receiver operating char-
acteristic curve) with SAS software (version 9.3).
Results
During the mean follow-up period of 13 years, there were
253 incident diabetes cases in the 3226 men. Table 1
shows the baseline characteristics and biological andmet-
abolic riskmarkers by quintiles of copeptin.Copeptinwas
significantly associated with WC, HOMA-IR, BP, blood
lipids (HDL-C and triglycerides), CRP, vWF, tPA, eGFR,
heart rate, andGGT.Noassociationwas seenwithplasma
glucose, glycated hemoglobin (HbA1c), or total or low-
density lipoprotein cholesterol.
Table 2 shows correlations between copeptin and bio-
markers shown to be associated with copeptin in the uni-
variate analysis, adjusted sequentially for age, WC, and
HOMA-IR. In age-adjusted analyses, copeptinwas signif-
icantly associated with WC, HOMA-IR, HOMA-, sys-
tolic BP, HDL-C, triglycerides, eGFR, GGT, CRP, vWF,
and tPA. With the exception of HDL-C, copeptin re-
mained significantly associated with these factors after
adjustment for age, WC, and HOMA-IR.
Figure 1 shows the Kaplan-Meier estimates of the cu-
mulative incidence of diabetes by fifths of copeptin. The
risk of diabetes was higher only in those in the top fifth of
the copeptin distribution. The age-adjusted relative risks
(95% confidence interval) for the 5 copeptin groups were
1.00 (reference), 0.86 (0.55–1.34), 1.30 (0.87–1.95), 1.12
(0.74–1.70), and 2.23 (1.54–3.22) across increasing
fifths. Because risk was only elevated in the top quintile,
we have presented the adjusted relative risk for the top
fifth vs the rest of the cohort in Table 3. The higher dia-
betes riskassociatedwith elevatedcopeptin remainedafter
adjustment for WC, lifestyle characteristics, social class,
renal function (eGFR), use of antihypertensive treatment,
statin use, systolic BP,GGT, triglycerides, CRP, and vWF.
Inclusion of tPA instead of vWF in the model made no
difference. Adjustment for HOMA-IR attenuated the di-
abetes risk further, but it remained significantly increased.
HOMA-IR and HOMA- are highly correlated, and ad-
justment forHOMA- insteadofHOMA-IRyielded iden-
tical results. Further adjustment for fasting glucose also
markedly attenuated the risk although the higher risk was
still significant. Additional adjustment for heart ratemade
no difference to the HR. The association remained signif-
icant even after further adjustment for HbA1c in model 5
(adjustedHR1.43 [1.06–1.93]). The increased riskwas
seen even after exclusion of men with evidence of chronic
kidney disease (eGFR of 60 mL/min/1.73 m2; n  472
(HRadjusted for variables inmodel 51.53 [1.10–2.11])
or after exclusion of men with preexisting CVD (myocar-
dial infarction, heart failure, or stroke; n 454) (adjusted
HR  1.40 [1.01–1.94]). When examined separately in
those with and without impaired fasting glucose (IFG)
(6.1 mmol/L), copeptin was strongly associated with
risk of diabetes in both groups after adjustment for age.
The association between copeptin and incident diabetes
was somewhat stronger in those without IFG at baseline
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after adjustment forHOMA-IRandmetabolic risk factors
(1.56 [1.04–2.34] vs 1.31 [0.82–2.07]) (Table 3). How-
ever, a formal test for interaction was not statistically sig-
nificant (P  .25).
Wealso examinedwhether copeptin improvedprediction
of diabetes beyond routine clinical parameters. The C-sta-
tistic for a model that included age, WC, smoking, hyper-
tension, use of statins, antihypertensive drugs, preexisting
CVD, renal function, GGT, triglycerides, and fasting blood
glucose was 0.779 (95% confidence interval [CI], 0.749–
0.809). There was no improvement in the C-statistic when
copeptin was added to themodel (C-statistic 0.779 [95%
CI, 0.749–0.809]; P [improvement] .58).
Discussion
In this study of older men, elevated plasma copeptin, a
surrogate marker for plasma AVP release, was signifi-
cantly associated with a higher risk of incident diabetes
independent of established diabetes risk factors. Our find-
ings confirm a previous report of an association between
copeptin and incident diabetes independent of fasting in-
sulin and fasting blood glucose (14) and extends this to
older adults aged 60 years. We were able to examine a
wide range of established risk markers and other relevant
pathways including hepatic enzymes (marking excess liver
fat) andmarkers of endothelial dysfunctionnot previously
assessed. The association between elevated copeptin levels
and risk of diabetes was, to a modest extent, mediated by
insulin resistance.
Data examining the prospective association between
copeptin and incident diabetes are limited, and the find-
ings have been inconsistent. The MDC Study in Sweden
showed a significant positive association between copep-
tin and incident diabetes even after adjustment for
fasting insulin and fasting blood glucose. In contrast, in
the PREVEND Study, a significant association was seen
between copeptin and risk of diabetes, which was abol-
ished after adjustment for components of the metabolic
syndrome includingWC, blood glucose, blood lipids, and
Table 1. Baseline Characteristics by Quintiles of Copeptin in Men With No Prevalent Diabetes
Copeptin Quintiles
Ptrend
<2.18 pmol/L
(n  647)
2.18–3.12 pmol/L
(n  643)
3.13–4.45 pmol/L
(n  648)
4.46–6.78 pmol/L
(n  642)
6.79 pmol/L
(n  646)
Age, y 67.7 (5.5) 68.4 (5.3) 68.6 (5.7) 68.9 (5.7) 69.4 (5.4) .0001
Body mass index,
kg/m2
25.9 (3.1) 26.3 (3.4) 26.6 (3.6) 27.0 (3.7) 27.5 (3.9) .0001
WC, cm 94.1 (9.4) 95.3 (9.4) 96.4 (9.9) 97.6 (9.9) 98.8 (10.5) .0001
% inactive 28.8 32.5 30.2 33.4 40.6 .0001
% smokers 10.9 12.6 13.9 13.6 13.5 .57
% heavy drinkers 3.2 2.5 3.5 4.7 3.3 .40
% parental history 26.2 27.4 26.7 25.9 25.9 .97
% manual workers 47.3 50.3 54.6 55.8 61.8 .0001
% statins 6.5 5.9 8.6 6.7 6.3 .33
% antihypertensive
drugs
26.6 28.2 28.5 31.6 43.1 .0001
% preexisting CVD 11.4 13.2 16.2 12.4 17.6 .0001
Biological markers
Systolic BP, mm Hg 145.5 (24.1) 146.6 (22.0) 149.2 (23.6) 150.5 (24.5) 149.6 (24.9) .0001
Cholesterol,
mmol/L
6.04 (1.00) 6.08 (1.18) 6.07 (1.04) 6.08 (1.11) 6.02 (1.11) .77
Triglyceride, mmol/L 1.44 (1.07–1.97) 1.52 (1.09–2.18) 1.56 (1.12–2.07) 1.63 (1.16–2.17) 1.61 (1.18–2.34) .0001
HDL-C, mmol/L 1.35 (0.33) 1.34 (0.34) 1.35 (0.33) 1.34 (0.35) 1.28 (0.34) .004
Glucose, mmol/L 5.53 (5.21–5.90) 5.53 (5.21–5.87) 5.58 (5.25–5.97) 5.53 (5.19–5.87) 5.58 (5.22–5.96) .26
HbA1c, % 4.85 (0.74) 4.81 (0.55) 4.81 (0.55) 4.86 (0.62) 4.89 (0.64) .09
Log HOMA-IR 0.56 (0.56) 0.60 (0.58) 0.66 (0.57) 0.69 (0.59) 0.84 (0.64) .0001
Heart rate, beats/min 62.82 (11.3) 64.59 (11.7) 65.81 (12.33) 65.17 (11.99) 67.04 (13.51) .0001
GGT, U/L 25.5 (18–35) 26.6 (18–36) 27.1 (18–36) 28.8 (19–37) 28.5 (20–40) .002
CRP, mg/L 1.27 (0.60–2.50) 1.52 (0.74–3.08) 1.46 (0.76–3.02) 1.79 (0.89–3.62) 2.20 (1.05–5.00) .0001
vWF, IU/dL 127.1 (41.1) 133.2 (42.7) 137.0 (43.3) 139.8 (43.7) 151.4 (48.2) .0001
tPa, ng/mL 9.37 (3.71) 10.39 (3.94) 11.00 (4.19) 11.14 (4.18) 11.54 (4.68) .0001
eGFR, mL/min/
1.73 m2
76.6 (11.0) 74.9 (13.0) 74.0 (11.1) 72.4 (13.0) 67.1 (14.1) .0001
% eGFR 60 7.3 8.7 9.1 15.1 28.1 .0001
Data are means (SD) or geometric means (interquartile range).
a Ptrend across groups.
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hypertension in men. A positive relationship persisted in
women only. In the FINRISK97 Study, a positive associ-
ation was seen between copeptin and diabetes after ad-
justment for established traditional diabetes risk factors
including glucose, but the trend was not significant (16).
However, glucose metabolism and related pathways may
be mechanisms by which copeptin increases diabetes risk
and the specific effects of these adjustments were not
shown.
Consistent with other studies, we have observed strong
cross-sectional associations between copeptin and eGFR,
liver enzymes, insulin resistance, and a cluster of cardio-
metabolic risk factors including hypertension, abdominal
obesity, and the dyslipidemia characteristic of insulin re-
sistance (high triglycerides and low HDL-C) (9–13). Co-
peptinwas strongly associatedwithheart rate (amarker of
increased sympathetic nervous system) and was also
strongly correlated with CRP (inflammation) and vWF (a
marker of endothelial dysfunction), factors shown to be
related to insulin resistance (17) and diabetes (18, 19).
However, copeptin correlated weakly with glucose levels
and HbA1c. The relationship between copeptin and dia-
betes was to a large extent explained by insulin resistance,
but there remained a significant independent association
even after adjustment for HOMA-IR and fasting plasma
glucose. Adjustment for insulin secretory function as
quantified by HOMA- instead of HOMA-IR yielded
identical results. As in the MDC Study, we also observed
somewhat stronger associations between copeptin and in-
cident diabetes in those without IFG after adjustment for
insulin resistance (14). This was also observed in the PRE-
VEND Study in women (16). Thus, mechanisms other
than glucose metabolism and insulin resistance may be
important for explaining this relationship. A possible ex-
planation for this findingmay relate to enhanced plasmin-
ogen activator inhibitor-1 (PAI-1) activity,whichhas been
shown to be predictive of diabetes independent of insulin
resistance (30). It is well documented that copeptin is as-
sociated with renal dysfunction, as was seen in this study
(31). There is evidence that mild or moderate renal insuf-
ficiency is associated with activation of inflammation and
Figure 1. Kaplan-Meier curve of cumulative diabetes incidence by
quintiles of copeptin in 3226 men without prevalent diabetes.
Table 2. Spearman Partial Correlation Coefficients
Between Copeptin and Biological Markers
Age
Adjusted
Age and WC
Adjusted
Age  WC 
HOMA-IR adjusted
WC 0.15a
HOMA-IR 0.16a 0.08a
HOMA- 0.14a 0.08a
Systolic BP 0.08a 0.04b 0.04b
Triglyceride 0.11a 0.06c 0.04b
HDL-C 0.06c 0.02 0.003
GGT 0.09a 0.07c 0.06b
CRP 0.16a 0.13a 0.12a
vWF 0.18a 0.17a 0.16a
tPa 0.15a 0.11a 0.09a
eGFR 0.29a 0.26a 0.28a
a P  .0001.
b P  .01.
c P  .001.
Table 3. Elevated Copeptin and Adjusted HR (95% CI)
of Incident Diabetes (Top Quintile vs the Rest)
Adjusted HR (95% CI)
<6.79
pmol/L
>6.79
pmol/L
All men
No. of men 2580 646
Rate/1000 person-years (n) 6.0 (174) 12.2 (79)
Model 1 1.00 1.81 (1.36–2.40)
Model 2 1.00 1.78 (1.34–2.37)
Model 3 1.00 1.61 (1.21–2.17)
Model 4 1.00 1.50 (1.11–2.01)
Model 5 1.00 1.47 (1.10–1.97)
No IFG
No. of men 2153 515
Rate/1000 person-years 4.4 (106) 7.2 (37)
Age-adjusted 1.00 1.73 (1.19–2.51)
Model 1 1.00 1.63 (1.10–2.42)
Model 2 1.00 1.69 (1.13–2.53)
Model 3 1.00 1.56 (1.04–2.34)
With IFG
No. of men 418 129
Rate/1000 person-years 14.3 (66) 31.1 (41)
Age-adjusted 1.00 1.86 (1.26–2.76)
Model 1 1.00 1.39 (0.88–2.18)
Model 2 1.00 1.31 (0.83–2.08)
Model 3 1.00 1.31 (0.82–2.07)
IFG  6.1 mmol/L). Model 1: adjusted for age, WC, cigarette
smoking, physical activity, social class, use of statins, antihypertensive
drugs, systolic BP, and eGFR. Model 2: model 1  GGT  triglyceride
 CRP  vWF. Model 3: model 2  HOMA-IR. Model 4: model 2 
plasma glucose. Model 5: model 2  HOMA-IR  plasma glucose.
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endothelial dysfunction (32). This is consistent with the
findings that copeptin correlated significantly with in-
flammation and with vWF and tPA (markers of endothe-
lial dysfunction) independently of insulin resistance. Up-
regulation of proinflammatory cytokines leads to
disturbances in the normal function of the vascular endo-
thelium reflected by increased secretion of endothelium-
derived products such as vWFandPAI-1,which have been
shown to be predictive of diabetes (18, 19, 30). The rela-
tion of PAI-1 to incident diabetes has been shown to be
stronger in subjects with normal glucose tolerance status
independent of insulin resistance (30), broadly consistent
with the findings seen for copeptin, and it may be that
copeptin and related perturbances may be more relevant
to early development of insulin resistance before mean-
ingful hyperglycemia is evident. The lower attenuation of
the association of copeptin with diabetes risk by adjust-
ment for HOMA-IR in men without IFG compared with
thosewith IFG (Table 3) is consistent with this possibility.
The association between copeptin and risk of incident di-
abetes in the present study was weaker than that observed
in the MDC Study (14) possibly because women were in-
cluded in their study, and there is the suggestion that the
association between copeptin and diabetes is stronger in
women (15). The lack of association seen in men in the
FINRISK97 Study and the PREVEND Study after adjust-
ment may relate to the age difference as the subjects in
these 2 studies were younger (average age of 50 years)
compared with subjects in the BRHS (average age of 69
years) and the MDC Study (average age of 59 years).
AVP is a key neurohormone that is synthesized in the
hypothalamus. AVP exerts its effect through 3 types of
receptors namely the V1 (vasoconstriction and myocar-
dial hypertrophy), the VIb (release of adrenocorticotropic
hormone), and the V2 receptor (water retention in the
renal collecting duct) (33). Several lines of evidence sup-
port a role for AVP in the pathogenesis of diabetes. Co-
peptin has been suggested as a marker of individual stress
(34). Activation of the hypothalamic-pituitary-adrenal
axis by AVP (copeptin) in chronic stress may be one of the
mediators of its association with adiposity and insulin re-
sistance, given the well-established link between gluco-
corticoids and glucose dysregulation. AVP also activates
V1b receptors on the -cells of the pancreatic islets to
increase the secretion of glucagon and potentiate insulin
release from the -cells of the pancreatic islets (5). With
aging, the hypothalamus and pituitary are less sensitive to
negative feedback from cortisol and both ACTH and cor-
tisol levels risewith age (35). It is possible that older adults
are more sensitive to the hypothalamic-pituitary-adrenal
axis reactivity to psychological stress than younger adults.
Thismay explain the positive association seen in this study
of older men and lack of association in the PREVEND
Study of younger men (15) after adjustment for metabolic
risk factors. AVP has a central role in the regulation of
water balance and AVP secretion per unit change in
plasma osmolality increases with aging (36). Copeptin in
older adults may also reflect low water intake, which has
been linked to the development of hyperglycemia (37).
Finally, it is interesting to note that elevated natriuretic
peptides (which cause natriuresis and diuresis) appear to
protect against diabetes as we reported using a genetic
approach (38), whereas this study demonstrates that high
levels of copeptin (indicating that AVP may be causing
antidiuretic effects andvasoconstriction) increasediabetes
risk. These findings further underline the potential novel
links between cardiac-related signals/natriuretic path-
ways and diabetes risk.
Strengths and limitations
The study population is socially representative of the
United Kingdom, and the follow-up rates in the BRHS are
exceptionally high. Further, we had excellent phenotyp-
ing, enabling us to adjust comprehensively for a range of
diabetes risk factors. The association between copeptin
and diabetes may be confounded by other factors such as
diet and sleep deprivation. Adjustment for dietary intake
of fiber based on self-reporting, which has been shown to
be related todiabetes in this study (39),madenodifference
to the findings. However, we did not have direct measures
of diet and we did not have measures of cortisol or sleep
deprivation, which may influence diabetes risk (40). Fu-
ture studies relating sleep disturbance and other dietary
markers would be useful to examine to what extent the
relationship of copeptins with diabetes was influenced by
such factors. Our study was carried out in an older pre-
dominantly white male population and we cannot gener-
alize our findings to women, younger men or other ethnic
groups. Diabetes incidence in this study relied on docu-
mented doctor-diagnosed cases of diabetes, which would
inevitably result in underascertainment of cases.Ourmea-
sure of insulin resistance was based on the standard, val-
idated HOMA method (27). However, the absence of di-
rect measures of insulin resistance (eg, based on glucose
clamp methods) could have led to an underestimation of
the true relationship between copeptin and incident
diabetes.
In conclusion, copeptin was strongly associated with
renal dysfunction, adiposity, insulin resistance, metabolic
risk factors, andmarkers of inflammation and endothelial
dysfunction. High copeptin levels are associated with sig-
nificantly higher risk of diabetes in older men which is to
some extent mediated through its effect on insulin and
related metabolic pathways. However, copeptin did not
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improve the prediction of incident diabetes beyond pre-
diction models with routine clinical parameters. The to-
tality of findings supports a potential role of the AVP sys-
tem in the pathogenesis of diabetes. Further studies using
aMendelian randomization approach (which uses genetic
single nucleotide polymorphisms linked to specific bio-
marker changes as instruments to help interrogate causal-
ity) could be helpful in examiningwhether there is a direct
causal associationbetween copeptin and insulin resistance
and copeptin and type 2 diabetes.
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